Icon

MYRBETRIQ (nda202611)- (25MG,50MG)

MIRABEGRON APGDI
25MG,50MG
Yes No
2030-Mar-28 2017-Jun-28
None None
None No
MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: ? Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ? Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more.
3 1 2
Total Other Developers 24
Drugs with Suitability No
25MG ** ** Up - 2
50MG ** ** Up - 2
NDA Sales Available Total Generic Sales Available
Yes 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ***** ******* *********** ****-*, **** **. ***, ***, ****** - **, ******* ******** ****, *****, ******, *********** ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.